The primary drug regulator in India, CDSCO is in charge of ensuring the efficacy, safety, and quality of medications dispensed throughout the nation. According to its results, these 50 medications—including Paracetamol—do not meet the recommended standards for a number of factors, including homogeneity and disintegration. This implies that these medications might not function as planned or might even be harmful to the users.
Askon Healthcare, located in Ujjain, Madhya Pradesh, is the manufacturer of the 500 mg paracetamol tablets that have been found to be inferior. On its official website, the company claims to have been manufacturing medicinal final dosage forms.
Emails and phone calls were placed to Askon Healthcare, but no one answered, according to the Mint report.
Based on a Central Drugs Standard Control Organization (CDSCO) drug warning for May, the drug samples were selected from Waghodia (Gujarat), Solan (Himachal Pradesh), Jaipur (Rajasthan), Haridwar (Uttarakhand), Ambala, Indore, Hyderabad, and Andhra Pradesh, among other places.
We have received an alert from CODSCO on the samples that failed, Our drug inspectors periodically take samples of medications, and the Cosmetic and Drug Act is used to pursue additional legal action against the pharmaceutical businesses that violate the law."
Manish Kapoor, State Drug Controller
"Himachal produces one out of every three drugs produced in the nation." He also stated that the medications' quality could not be harmed.
The DCGI list also includes the antihypertensive drug Telmisartan, the amlodipine IP tablets, the injection of Dexamethasone Sodium Phosphate I.P. for the treatment of autoimmune diseases and severe infections, and the 0.5 mg IP tablets of Clonazepam for the treatment of neurological complications. The drug samples were examined by state and central laboratories alike.
(Input from various sources)
(Rehash/Priyanka Pandey/MSM)
